【Objective】 A prospective,multi-center,controlled study was performed to evaluate the effectiveness and possible side effects of oral erythromycin (EM) in treating preterm infants,especially VLBW(very low birth-weight )preterm infants with feeding intolerance(FI). 【Methods】 46 preterm infants with FI from 16 hospitals were enrolled,study period from January,2008 to March,2010.The patients were divided into 3 random groups:EM-HD group,oral erythromycin 12.5 mg/kg,q8h for 7~10 days; EM-LD group,oral erythromycin 5 mg/kg,therapy as above; and control group,not treated by any gastrointestinal prokinetic agent.Several critical time points of feeding condition were compared,the incidence of extrauterine growth retardation (EUGR) and the potential adverse effects of erythromycin were also evaluated. 【Results】 11 patients had be classed as EM-HD group,22 as EM-LD group,13 as control.After enrollment,the time reaching 50 kCal/(kg·d) from enteral feeding were significantly shorter and the proportions of calorie ingested by the enteral route when the infants regained to their birth weight were significantly higher in two trial groups than the control group.The incidence of EUGR was significantly lower in EM-HD group.All enrolled infants were followed up from discharge to 6 months' age,no obvious side effect was found in the trial groups. 【Conclusions】 In this research,both doses of oral erythromycin are effective for treating VLBW preterm infants with FI and the high dose is more effective.There are not obvious side effects of oral erythromycin observed.
Key words
erythromycin /
very low birth-weight infant /
preterm /
feeding intolerance
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Berseth CL.Gastrointestinal motility in the neonate[J].Clin Perinatol,1996,23(2):179-190.
[2] Oei J,Lui K.A placebo-controlled trial of low-dose erythromycin to promote feed tolerance in preterm infants[J].Acta Paediatr,2001,90(8):904-908.
[3] Ng PC,So KW,Fung KS,et al.Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants[J].Arch Dis Child Fetal Neonatal Ed,2001,84(3):177-182.
[4] Ng PC,Lee CH,Wong SP,et al.High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants[J].Gastroenterology,2007,132(5):1726-1739.
[5] Elhennawy AA,Sparks JW,Armentrout D,et al.Erythromycin fails to improve feeding outcome in feeding-intolerant preterm infants[J].J Pediatr Gastroenterol Nutr,2003,37(3):281-286.
[6] Ng SC,Gomez JM,Rajadurai VS,et al.Establishing enteral feeding in preterm infants with feeding intolerance:a randomized controlled study of low-dose erythromycin[J].J Pediatr Gastroenterol Nutr,2003,37(5):554-558.
[7] Nuntnarumit P,Kiatchoosakun P,Tantiprapa W,et al.Efficacy of oral erythromycin for treatment of feeding intolerance in preterm infants[J].J Pediatr,2006,148(5):600-605.
[8] Dellagrammaticas HD,Iacovidou N,Megaloyanni E,et al.Effect of low-dose oral erythromycin on gastric aspirates in ventilated neonates less than 32 weeks of gestation.Preliminary results[J].Biol Neonate,2002,81(3):213-216.
[9] Xu L,Depoortere I,Vertongen P,et al.Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor[J].Biochem Pharmacol,2005,70(6):879-887.
[10] Peeters TL.Erythromycin and other macrolides as prokinetic agents[J].Gastroenterology,1993,105(6):1886-1899.
[11] Weber FJ,Richards RD,Mccallum RW.Erythromycin:a motilin agonist and gastrointestinal prokinetic agent[J].Am J Gastroenterol,1993,88(4):485-490.
[12] Coulie B,Tack J,Peeters T,et al.Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans[J].Gut,1998,43(3):395-400.
[13] Gouyon JB,Benoit A,Betremieux P,et al.Cardiac toxicity of intravenous erythromycin lactobionate in preterm infants[J].Pediatr Infect Dis J,1994,13(9):840-841.
[14] Maheshwai N.Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis?[J].Arch Dis Child,2007,92(3):271-273.
[15] Curry JI,Lander TD,Stringer MD.Review article:erythromycin as a prokinetic agent in infants and children[J].Aliment Pharmacol Ther,2001,15(5):595-603.
[16] Westphal JF,Vetter D,Brogard JM.Hepatic side-effects of antibiotics[J].J Antimicrob Chemother,1994,33(3):387-401.
PDF(576 KB)
